Navigation Links
Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe

OSAKA, Japan, Oct. 1 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda Pharmaceuticals Nordics AB (Sweden), and Takeda Pharmaceuticals Benelux SPRL (Belgium) - are part of Takeda's strategic global expansion efforts.

"Takeda has a significant opportunity to expand our presence in Mexico, Europe and other priority markets," said Alan MacKenzie, Executive Vice President (EVP) International Operations, Takeda Pharmaceuticals International, Inc. "Executing our territory expansion strategy is an important step toward further globalizing our operations and enhancing our ability to bring important medicines to patients who need them."

The Mexican pharmaceutical market is the 12th largest in the world and accounts for approximately 25 percent of the pharmaceutical sales throughout Latin America. The population in Mexico is increasing, and access to healthcare continues to grow, with the market increasing faster than in the United States and Europe, making it a key region for Takeda's expansion.

Nordics and Benelux are strategically important regions in Europe - Norway, Sweden, Denmark, Belgium and Luxembourg have a combined pharmaceutical market size which accounts for five percent of the European pharmaceutical market. Following the buy-back of Actos® (pioglitazone) in October 2008, Takeda will be distributing Actos in the five countries. The creation of these commercial subsidiaries will further increase Takeda's reach in the regions.

The Turkish pharmaceutical market is one of the largest global pharmaceutical markets, ranked sixth in Europe and 13th worldwide with the fastest forecasted growth rate in Europe over the next five years. Takeda also recently re-acquired the rights to Actos in this market, providing the business with a strong product with which to enter the market.

Overall, the new subsidiaries will accelerate Takeda's expansion efforts for core products including Actos and reinforces Takeda's global operating infrastructure. The company will work toward the earliest possible approval and launch of new products in these regions. Takeda's presence in these seven new countries builds upon other expansions announced in 2009 including commercial operations in Spain, Portugal, Ireland, and Canada.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Takeda is enhancing its R&D pipeline by concentrating its management resources in the following selected core therapeutic areas: lifestyle-related diseases, oncology and urological diseases (including gynecology), central nervous system diseases (including bone and joint disorders), and gastroenterological diseases. For more information, please visit

About Takeda Pharmaceuticals Mexico, S.A. de C.V.

    Name:           Takeda Pharmaceuticals Mexico, S.A. de C.V.
    Location:      Mexico city, Mexico
    Established:  October 2009

About Takeda Pharmaceuticals Nordics AB

    Name:           Takeda Pharmaceuticals Nordics AB
    Location:      Sweden
    Established:  October 2009

About Takeda Pharmaceuticals Benelux SPRL

    Name:           Takeda Pharmaceuticals Benelux SPRL
    Location:      Belgium
    Established:  October 2009

About Takeda Pharmaceuticals Trade, LLP

    Name:           Takeda Pharmaceuticals Trade, LLP
    Location:      Istanbul, Turkey
    Established:  October 2009

SOURCE Takeda Pharmaceutical Company Limited

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
2. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
3. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
4. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
5. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
8. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
9. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Post Your Comments:
(Date:10/13/2015)...  Yesterday Congresswoman Renee Ellmers (R-NC-02) visited ... located in Holly Springs, NC . ... ® (Influenza Vaccine) using cell-culture technology, a state-of-the-art production ... is not reliant on chicken eggs. 1,2 On ... business of Novartis AG in the US, which for ...
(Date:10/13/2015)... -- XiMo AG ( Lucerne , ... Milpitas, California ) announced today the launch of ... of metathesis chemistry was highlighted by the Nobel Prize ... This industrially-relevant application has been utilized in the production ... and polymers. Georg Fráter , COO of ...
(Date:10/12/2015)... , October 13, 2015 the ... be operating in a non-clinical capacity. --> the ... be operating in a non-clinical capacity. --> The University ... completed installation of the first high field (1.5 Tesla) MRI-guided linear ... next year, the system will be operating in a non-clinical capacity. ...
Breaking Medicine Technology:
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... Dr. ... by Medical New Today on September 18, 2015. The research, which was conducted at ... Dr. Wael Sabbah and colleagues, show connections between stress during pregnancy and future dental ...
(Date:10/13/2015)... , ... October 13, 2015 , ... A child without ... why SmileCareClub , the leading remote invisible aligner system, has joined with ... otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will donate one ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... today their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference ... Valley Ranch and will unite customers, partners, WennSoft team members and sponsors to ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra Health ... 59,000 emergency department visits per year, today announced the successful and rapid deployment ... clinical, operational and financial outcomes. , In less than four days, ...
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ... of the university’s new School of Nursing. Dr. McLeod—who earned her Doctor of ... in nursing and education that has spanned four decades. , Dr. McLeod’s long ...
Breaking Medicine News(10 mins):